초록 ▼

This invention provides a composition comprising an effective amount of (1-3)-β-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for tre

This invention provides a composition comprising an effective amount of (1-3)-β-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject.

대표청구항 ▼

What is claimed is: 1. A composition comprising: (a) a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; and (b) an orally administered composition comprising a 1,3-β glucan derived from barley in an amount effective to enhance th

What is claimed is: 1. A composition comprising: (a) a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; and (b) an orally administered composition comprising a 1,3-β glucan derived from barley in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier; wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3. 2. The composition of claim 1 wherein compositions (a) and (b) are administered to the subject concurrently or sequentially. 3. The composition of claim 1, wherein the antibody is a monoclonal antibody. 4. The composition of claim 1, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response. 5. The composition of claim 1, wherein the antibody is directed to a cancer cell expressing the antigen EGFR. 6. The composition of claim 1, wherein the antibody is directed to a cancer cell expressing the antigen GD2. 7. The composition of claim 1, wherein the antibody is directed to a cancer cell expressing the antigen GD3. 8. The composition of claim 1, wherein the antibody is directed to a cancer cell expressing the antigen CD20. 9. The composition of claim 1, wherein the antibody is directed to a cancer cell expressing the antigen HER2. 10. The composition of claim 1, wherein the cancer cell expressing CD20 is non-Hodgkin's lymphoma, Hodgkin's lymphoma, or Epstein-Barr related lymphoma. 11. The composition of claim 10, wherein the lymphoma is non-Hodgkin's lymphoma. 12. The composition of claim 5, wherein the cancer cell expressing the EGFR is an epidermoid cancer cell. 13. The composition of claim 6, wherein the cancer cell expressing the antigen GD2 is a neuroblastoma. 14. The composition of claim 7, wherein the cancer cell expressing the antigen GD3 is a melanoma cancer cell. 15. The composition of claim 9, wherein the cancer cell expressing the antigen HER2 is a breast cancer cell. 16. The composition of claim 1, wherein the amount of the orally administered 1,3-β glucan is about >=25 mg/kg/day, five days a week for a total of 2-4 weeks. 17. A composition comprising: (a) a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; an (b) an orally administered composition comprising a 1,3-β glucan derived from barley in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier; wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma. 18. The composition of claim 17, wherein compositions (a) and (b) are administered to the subject concurrently or sequentially. 19. The composition of claim 17, wherein the antibody is a monoclonal antibody. 20. The composition of claim 17, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response. 21. The composition of claim 17, wherein the antibody is directed to EGFR (epidermal growth factor receptor). 22. The composition of claim 17, wherein the antibody is directed to antigen GD2. 23. The composition of claim 17, wherein the antibody is directed to antigen GD3. 24. The composition of claim 17, wherein the antibody binds to the antigen CD20. 25. The composition of claim 17, wherein the antibody binds to the antigen HER2. 26. The composition of claim 17, wherein the amount of the orally administered β glucan is about >=25mg/kg/day, five days a week for a total of 2-4 weeks.